EverSource Wealth Advisors’s Nektar Therapeutics NKTR Stock Holding History

EverSource Wealth Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.66K	Sell	81 -30	-27%	-$2.19K	﹤0.01%	3227
2026 Q1	$7.99K	Buy	111 +1	+0.9%	+$57	﹤0.01%	3037
2025 Q4	$4.65K	Hold	110	–	–	﹤0.01%	3155
2025 Q3	$6.26K	Sell	110 -700	-86%	-$23.2K	﹤0.01%	3048
2025 Q2	$20.9K	Buy	810 +717	+771%	+$8.05K	﹤0.01%	2252
2025 Q1	$945	Buy	93 +82	+745%	+$1.07K	﹤0.01%	3248
2024 Q4	$159	Buy	+11	New	+$194	﹤0.01%	3476
2022 Q2	–	Sell	-31	Closed	-$3K	–	1833
2022 Q1	$3K	Buy	31 +11	+55%	+$1.63K	﹤0.01%	1433
2021 Q4	$4K	Buy	+20	New	+$4.34K	﹤0.01%	1348

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EverSource Wealth Advisors's NKTR Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Nektar Therapeutics (NKTR) stake by 27% in Q2 2026, selling an estimated $2.19K and leaving 81 shares worth $5.66K. The position accounts for ﹤0.01% of the portfolio, ranked #3227.

EverSource Wealth Advisors first reported a position in NKTR in Q4 2021 and has held it in 9 quarters since. The position peaked at $20.9K in Q2 2025. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

EverSource Wealth Advisors held 81 shares of Nektar Therapeutics worth $5.66K as of Q2 2026.
EverSource Wealth Advisors sold 30 Nektar Therapeutics shares in Q2 2026, an estimated $2.19K.
Nektar Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3227 holding.
EverSource Wealth Advisors first reported a position in Nektar Therapeutics in Q4 2021 and has held it in 9 quarters since.
EverSource Wealth Advisors's Nektar Therapeutics position peaked at $20.9K in Q2 2025.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.